Study of Cancer

Focus on Mikhail Blagosklonny’s Research on Aging and Cancer

trop / April 17, 2017

Education and Work

Mikhail Blagosklonny is an expert in oncology. His studies revolve mostly around aging and cancer. Presently, he is a professor of Oncology at Roswell Park Cancer Institute. He attended the First Pavlov State Medical University, St. Petersburg and got awarded with M.D. and Ph.D. He studied experimental medicine and cardiology. He started off his career at the New York Medical College in 2002 holding the position of Associate Lecturer in Medicine. He then moved to Ordway Research Institute assuming the position of senior scientist. Mikhail remained at Ordway until 2009 when he moved to Roswell Park Cancer Institute to teach oncology. Follow Mikhail on Loop

Studies on Cancer and Aging

Mikhail Blagosklonny has an interest in a number of studies including aging and cancer. His research mainly focuses on the beleaguered cancer therapies that shield the healthy cells from damage by radioactive rays and chemotherapy, aging mechanism (biogerontology) and anti-aging cures. In addition, he has other interests in researching clinical investigations as well as cellular and molecular biology. His research focuses on anti-cancer therapeutics, cellular senescence, signal transduction and cell cycle. Blagosklonny’s passion enabled him to study signal transduction conduits that lead from cancer to aging. He has managed to stumble upon prospective targets that can help in slowing down age-related illnesses and the aging process.

Possible Role of TOR Signaling

Stemming from his interest in researching about aging and cancer, Mikhail Blagosklonny has formulated a theory about the possible role of TOR in the two areas. He posits that TOR signaling has a high possibility of treating aging and cancer. He pointed out that rapamycin, a major cancer drug can be used as a treatment to extend an individual’s life.

Mikhail Blagosklonny’s Editorial Works

Mikhail Blagosklonny is involved in various editorial works. He is a chief author in cell cycle, aging and oncotarget. He is also the assistant editor of cancer therapy and biology. Blagosklonny is the founding and chief editor of International Journal of Cancer, cancer research, American Journal of Pathology, Cell death and differentiation, Autophagy and American Journal of Pathology. Oncotarget refers to a medical journal published weekly covering oncology research. It was launched in 2010 and its chief editors are Mikhail Blagosklonny and Andrei V. Gudkov from Roswell Park Cancer Institute. Mikhail has so far written over 170 research articles.

Read more: